ArticleClinical pharmacology and therapeutics2026
Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2 (TROP2)-directed antibody-drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior therapies. Exposure-response (ER) analyses were conducted using Phase 1-3 clinical data from patients with NSCLC (efficacy and safety) or breast cancer (BC) (only safety). Parametric time-to-event models were developed for overall survival (OS), progression-free survival (PFS), and adverse events of special interest (AESI). Logistic regression models were used for overall response rate (ORR), Grade ≥ 3 treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs associated dose reduction. Covariate effects were assessed using stepwise selection. A significant linear ER relationship was found between Dato-DXd AUC in the first cycle (AUC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.